Sarah Pringle

Sarah Pringle is a senior reporter focused on M&A, private equity and auctions in the healthcare industry. Prior to joining The Deal, Pringle reported on U.S. and Canadian equity markets at Bloomberg News in New York and MarketWatch in San Francisco.

Recent Articles By The Author

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Why Allergan is Fine Without Large M&A

Why Allergan is Fine Without Large M&A

The Dublin-based drugmaker has some 65-plus mid-to-late stage assets in its pipeline.

Glaucoma Treatment Maker a $95M

Glaucoma Treatment Maker a $95M "Stepping Stone" for Allergan

The deal for ForSight VISION5 aligns with the bolt-on M&A strategy described by CEO Brent Saunders earlier this week.

Why Hendrickson-Led Perrigo Is A Good Bet For Long Term Investors

Why Hendrickson-Led Perrigo Is A Good Bet For Long Term Investors

Despite cutting its full year guidance, the company continues to have a lot of potential upside.

Press Ganey to Change Hands Months After IPO

Press Ganey to Change Hands Months After IPO

Despite a seemingly meager premium on the $2.35 billion deal, seller Vestar likely fared well after the healthcare technology company's stock appreciated more than 60% over the past 15 months.